Yuanbo Lan

Prof. Dr. Yuanbo Lan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FZFan Zou
Fan Zou
ZCZhiwei Cui
Zhiwei Cui
SLSiyu Lou
Siyu Lou
YOYingyong Ou
Yingyong Ou
CZChengyu Zhu
Chengyu Zhu
YLYuanbo Lan
Yuanbo Lan
Introduction: Linezolid is an oxazolidinone antibiotic that is active against drug-resistant Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis. Real-world studies on the safety of linezolid in large populations are lacking. This study aimed to determine the adverse events associated with linezolid in real-world settings by analyzing data from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).Methods: We retrospectively extracted reports on adverse drug events (ADEs) from the FAERS database from the first quarter of 2004 to that of 2023. By using disproportionality analysis including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), along with the multi-item gamma Poisson shrinker (MGPS), we evaluated whether there was a significant association between linezolid and ADE. The time to onset of ADE was further analyzed in the general population and within each age, weight, reporting population, and weight subgroups.Results: A total of 11,176 reports of linezolid as the “primary suspected” drug and 263 significant adverse events of linezolid were identified, including some common adverse events such as thrombocytopenia (n = 1,139, ROR 21.98), anaemia (n = 704, ROR 7.39), and unexpected signals that were not listed on the drug label such as rhabdomyolysis (n = 90, ROR 4.33), and electrocardiogram QT prolonged (n = 73, ROR 4.07). Linezolid-induced adverse reactions involved 27 System Organ Class (SOC). Gender differences existed in ADE signals related to linezolid. The median onset time of all ADEs was 6 days, and most ADEs (n = 3,778) occurred within the first month of linezolid use but some may continue to occur even after a year of treatment (n = 46).Conclusion: This study reports the time to onset of adverse effects in detail at the levels of SOC and specific preferred term (PT). The results of our study provide valuable insights for optimizing the use of linezolid and reducing potential side effects, expected to facilitate the safe use of linezolid in clinical settings.

23 July 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QLQuanxian Liu
Quanxian Liu
LHLu Huang
Lu Huang
HYHong Yan
Hong Yan
ZZZhaojing Zong
Zhaojing Zong
ZCZhenyong Chen
Zhenyong Chen
YLYuanbo Lan
Yuanbo Lan
Objective: To analyze the clinical and laboratory characteristics and to identify predictors of moderate to severe anti-tuberculosis drug-induced liver injury (ATB-DILI) in patients with tuberculosis.Methods: This prospective study enrolled Tuberculosis (TB) patients treated with first-line anti-tuberculosis drugs at the Affiliated Hospital of Zunyi Medical University between May 2022 and June 2023. The occurrence of ATB-DILI was monitored, and demographic and clinical data were gathered. We analyzed risk factors for the development of moderate to severe ATB-DILI.Results: ATB-DILI was detected in 120 (10.7%) of the patients, with moderate to severe ATB-DILI occurring in 23 (2.0%) of the 1,124 patients treated with anti-tuberculosis treatment. Multivariate cox regression analysis identified malnutrition (HR = 4.564, 95% CI: 1.029–20.251, p = 0.046) and hemoglobin levels <120 g/L (HR = 2.825, 95% CI: 1.268–11.540, p = 0.017) as independent risk factors for moderate to severe ATB-DILI.Conclusion: The incidence of moderate to severe ATB-DILI was found to be 2.0%. Malnutrition and hemoglobin levels below 120 g/L emerged as significant independent risk factors for the occurrence of moderate to severe ATB-DILI in this patient population.

17 November 2025 in Chinese Medical Journal
Verified
Journal Article
Open access
MWMinggui Wang
Minggui Wang
MLMei Liu
Mei Liu
DWDan Wang
Dan Wang
DYDanni Yang
Danni Yang
YZYiwei Zeng
Yiwei Zeng
QWQinglan Wang
Qinglan Wang
Recent advancements in cancer therapeutics, including targeted therapies and immunotherapies, have significantly improved treatment outcomes but remain limited by challenges such as off-target toxicity, poor penetration into deep tumor tissues, and the emergence of drug resistance. Engineered bacteria-based cancer therapies present a novel and versatile approach to address these limitations. Leveraging their ability to selectively colonize tumor microenvironments, bacteria can elicit antitumor immune responses and serve as platforms for the localized delivery of therapeutic agents. Through genetic engineering and synthetic biology, bacteria can be programmed to produce anticancer payloads tailored to clinical needs. This review highlights recent progress in the design and application of engineered bacteria for cancer therapy, emphasizing innovative strategies to enhance therapeutic delivery and efficacy. In addition, we discuss the integration of bacteria-based approaches with conventional therapies to overcome intratumor heterogeneity and improve treatment outcomes. Finally, we discuss insights from past and ongoing clinical trials of tumor-targeting bacteria, alongside challenges that must be surmounted to realize their full therapeutic promise.

29 March 2019 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
YLYuanbo Lan
Yuanbo Lan
LCLing Chen
Ling Chen
HZHong Zhang
Hong Zhang
Extrapulmonary tuberculosis (EPTB) accounted for 14% of 6.4 million cases of TB that were reported to WHO in 2017, and genitourinary TB (GUTB) is the second most common type of EPTB. The most common site of GUTB is the kidneys and testicular TB is relatively rare. The case of one patient with pulmonary and testicular TB caused separately by two different genotypes of Mycobacterium tuberculosis (Mtb) is further rare. Here, we present an unusual case of TB in which pulmonary TB (PTB) and testicular TB were caused by Mtb isolates with two different genotypes in a 91-year-old male patient from Zunyi, Guizhou Province of China. A better understanding of the mechanism by which a small number of tubercle bacilli are spread from the primary site of PTB to more distant parts/organs of the body, and what factors determine the potential EPTB site will provide us with new ways to prevent and control EPTB infections.

6 February 2026 in Clinical Therapeutics
Verified
Journal Article
Closed access
ZCZhenyong Chen
Zhenyong Chen
CZChengyu Zhu
Chengyu Zhu
ZCZhiwei Cui
Zhiwei Cui
FZFan Zou
Fan Zou
YLYuanbo Lan
Yuanbo Lan

15 August 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GXGuangyan Xu
Guangyan Xu
FZFan Zou
Fan Zou
YLYuanbo Lan
Yuanbo Lan
Introduction: Pulmonary mucinous epithelioid carcinoma (PMEC) is a rare malignancy that typically progresses slowly and has a favorable prognosis. In contrast, adrenal sarcomatoid carcinoma (ASC) is an aggressive and uncommon cancer with poor outcomes. The coexistence of low-grade PMEC and metastatic ASC is exceedingly rare and presents unique clinical challenges, with limited treatment options and poor prognosis. This case report highlights the diagnosis and management of a patient with long-term, slow-progressing low-grade PMEC and rapidly progressing metastatic ASC.Case presentation: A 44-year-old male with a 20-year history of intermittent respiratory symptoms developed abdominal pain and imaging findings indicative of adrenal metastasis and multiple bone metastases. Initial diagnosis through CT and PET-CT scans raised suspicion for pulmonary tumors, and subsequent biopsies confirmed low-grade PMEC in the lungs. In 2023, further diagnostic work revealed a sarcomatoid carcinoma (SC) in the left adrenal gland. Molecular testing revealed BRAF p.V600E mutations across lung, adrenal, and plasma samples, providing critical insight into the nature of the metastatic spread. Despite treatment with molecular therapy (dabrafenib + trametinib) and radiotherapy, the patient’s conditioan deteriorated rapidly, and he passed away in September 2023.Discussion: This rare case underscores the importance of the BRAF p.V600E mutation in guiding therapy in cases of coexisting PMEC and ASC. The consistent presence of BRAF mutations in lung, adrenal, and plasma samples provided molecular evidence of the metastatic process, offering guidance for targeted therapy. Despite the potential of molecular therapy, the limited treatment efficacy suggests that further research is needed to better identify patient populations that may benefit from targeted therapies for advanced PMEC. BRAF mutations play a significant role in treatment decision-making and should be considered in clinical practice for these complex cases.Conclusion: This case highlights the complexity of diagnosing and treating coexisting low-grade PMEC and metastatic ASC, with the BRAF p.V600E mutation offering valuable molecular insights for therapy. Treatment strategies should be personalized, and future studies are needed to refine therapeutic approaches for such complex cases.